2-D DIGE to expedite downstream process development for human monoclonal antibody purification

Area of Science:

• Biotechnology
• Proteomics
• Biopharmaceutical Manufacturing

Background:

• Two-dimensional fluorescence difference gel electrophoresis (2-D DIGE) is a key technique for analyzing protein expression.
• Understanding host-cell protein (HCP) profiles is crucial for biopharmaceutical development and quality control.
• Recombinant monoclonal antibodies, like IgG1, are vital therapeutics requiring robust production processes.

Purpose of the Study:

• To apply 2-D DIGE for developing a purification process for a recombinant anti-Rhesus D IgG1 antibody.
• To quantitatively assess the impact of expression clone variability and cell viability on HCP patterns.
• To validate the purification scheme by analyzing protein profiles post-purification.

Main Methods:

• Utilized 2-D DIGE to analyze protein expression profiles from Chinese hamster ovary (CHO) cell cultures.
• Compared protein patterns between different expression clones and varying levels of cell viability.
• Performed quantitative analysis of identified protein spots (up to 800).
• Analyzed purified IgG samples using 2-D DIGE to confirm purification efficacy.

Main Results:

• Cell viability demonstrated a greater influence on the host-cell protein expression pattern than the specific expression clone used.
• Identified and analyzed up to 800 distinct protein spots.
• Purified IgG samples from different culture conditions exhibited identical protein patterns on 2-D DIGE.
• The purification process was validated by the consistent protein profiles of the purified antibody.

Conclusions:

• Cell viability is a critical factor influencing HCP profiles in CHO cell cultures during recombinant antibody production.
• 2-D DIGE is a powerful tool for process development, enabling quantitative assessment of protein expression variability.
• The developed purification strategy effectively removed process-related impurities, yielding a consistent, purified recombinant IgG1 antibody.